DNA Gyrase Subunit B (EC 126.96.36.199) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'DNA Gyrase Subunit B (EC 188.8.131.52) - Pipeline Review, H1 2016', provides in depth analysis on DNA Gyrase Subunit B (EC 184.108.40.206) targeted pipeline therapeutics. The report provides comprehensive information on the DNA Gyrase Subunit B (EC 220.127.116.11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in DNA Gyrase Subunit B (EC 18.104.22.168) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 22.214.171.124) - The report reviews DNA Gyrase Subunit B (EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in DNA Gyrase Subunit B (EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects - The report assesses DNA Gyrase Subunit B (EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 220.127.116.11) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 18.104.22.168) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 22.214.171.124) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 DNA Gyrase Subunit B (EC 126.96.36.199) Overview 6 Therapeutics Development 7 DNA Gyrase Subunit B (EC 188.8.131.52) - Products under Development by Stage of Development 7 DNA Gyrase Subunit B (EC 184.108.40.206) - Products under Development by Therapy Area 8 DNA Gyrase Subunit B (EC 220.127.116.11) - Products under Development by Indication 9 DNA Gyrase Subunit B (EC 18.104.22.168) - Pipeline Products Glance 10 Early Stage Products 10 Unknown Stage Products 11 DNA Gyrase Subunit B (EC 22.214.171.124) - Products under Development by Companies 12 DNA Gyrase Subunit B (EC 126.96.36.199) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 DNA Gyrase Subunit B (EC 188.8.131.52) - Companies Involved in Therapeutics Development 18 Abgentis Limited 18 AstraZeneca Plc 19 Daiichi Sankyo Company, Limited 20 Merck & Co., Inc. 21 DNA Gyrase Subunit B (EC 184.108.40.206) - Drug Profiles 22 DS-2969 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 GP-4 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Small Molecule to Inhibit DNA Gyrase Subunit B for Bacterial Infections - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecules to Inhibit DNA Gyrase B for Tuberculosis - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules to Inhibit DNA GyrB for Tuberculosis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 VXc-100 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 VXC-486 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 DNA Gyrase Subunit B (EC 220.127.116.11) - Featured News & Press Releases 30 Sep 12, 2012: Trius Therapeutics Reports Preclinical Data On Broad-Spectrum Antibiotics At 52nd Annual ICAAC Meeting 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Comparative Analysis by Unknown Stage Development, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by Abgentis Limited, H1 2016 18 Pipeline by AstraZeneca Plc, H1 2016 19 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 20 Pipeline by Merck & Co., Inc., H1 2016 21
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.